SpyGlass Pharma

SpyGlass Pharma is a late-stage biopharmaceutical company focused on transforming the treatment of chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company's proprietary non-bioerodible drug delivery platform is designed to work with various well-established approved medicines, including bimatoprost and other small molecules, to potentially treat a range of conditions in the front and back of the eye. Its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is a novel intraocular lens with attached drug pads designed to be implanted during routine cataract surgery to deliver three years of bimatoprost for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The BIM-IOL System is currently in two parallel registrational Phase 3 clinical trials. The company's next-generation candidate, the Bimatoprost Drug Ring System (BIM-DRS), targets the broader pseudophakic glaucoma patient population. SpyGlass Pharma is pre-revenue and trades on the Nasdaq. The company was founded in 2019 by Malik Y. Kahook, M.D. and Glenn Sussman, with its platform originally developed at the Sue Anschutz-Rodgers Eye Center at the University of Colorado Anschutz School of Medicine. Updated Aug 6, 2026